AIHTA - Publications - Search - The Role of Public Contributions to the Development of Health Innovations

Wild, C. and Fabian, D. (2024): The Role of Public Contributions to the Development of Health Innovations. HTA-Projektbericht 158.

[thumbnail of HTA-Projektbericht_Nr.158.pdf]
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader

New (pharmaceutical) products are becoming increasingly more expensive. As a result of this trend accessibility of pharmaceuticals decreases. However, not all innovation can be attributed to private companies. Subsequently, the role of public institutions such as universities, university spin-offs, and publicly funded biotech start-ups is largely being disregarded during price negotiations. Public funding in the form of research grants, tax incentives, utilisation of clinical infrastructure or regulatory measures make a major contribution.

Article 57 of the proposed Pharmaceutical Legislation (PL, Directive) will require market authorisation applicants to publicly declare any direct financial support for R&D received from public authorities. The aim of our research (funded by EU Horizon Europe Grant Agreement Number 101095593) is to increase transparency in (pharmaceutical) R&D to mitigate the risk of market failure associated with information asymmetry by analysing pharmaceutical R&D expenditures for bringing a new medicine to market and which factors influence these expenditures and to identify the categories needed to capture direct or indirect public contributions to R&D. Our findings are intended to provide a framework for standardised reporting of public contributions and to reduce ambiguity in the interpretation of "direct" and "indirect" public contributions.

The report is the first output of the project HI-PRIX (WP2, sub-deliverable 2.2)

Item Type:Project Report
Additional Information:
Keywords:R&D, innovation research, public contributions, product development, pharmaceuticals
Subjects:QV Pharmacology, toxicology, pharmacy > QV 701-737 Pharmacy
W Health professions > W 74-80 Medical economics. Health care costs
WA Public health > WA 525-590 Health administration and organisation
WB Practice of medicine > WB 102 Evidence-based medicine
Series Name:HTA-Projektbericht 158
Deposited on:07 Feb 2024 11:55
Last Modified:07 Feb 2024 11:55

Repository Staff Only: item control page